Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes
Authors' conclusion
Enavogliflozin treatment decreased leptin over 24 weeks in patients with type 2 diabetes, and this effect remained significant after adjusting for weight change, suggesting an improved adipokine profile. Reductions in leptin were also associated with improvements in insulin resistance and increases in serum ketone levels. These results highlight enavogliflozin as a potential treatment beyond glycemic control, offering additional benefits in managing metabolic dysregulation associated with type 2 diabetes.
Study context
- Population
- Patients with T2D
- Comparison
- Enavogliflozin vs placebo
- Primary endpoint
- Changes in serum adiponectin and leptin
- Follow-up
- 24 weeks
Methodological detailsdouble-blind, placebo-controlled, post hoc analysis
- Double-blind
- Placebo-controlled
- Post hoc analysis
Primary result
As reported in the abstract
Least squares (LS) mean difference (adiponectin)
0.98 mg/L
increased adiponectin with enavogliflozin
LS mean difference (leptin)
−2.99 µg/L
significant decrease in leptin
Further findings
Adipokines adjusted for weight change · 24 weeks
- Enavogliflozin significantly reduced leptin after adjusting for weight change
- Adiponectin changes not significant after adjusting for weight change
Adipokines across weight loss categories
- Adiponectin significantly increased across weight loss categories; leptin showed no significant differences
Correlations of leptin change with metabolic parameters · 24 weeks
- Leptin change positively correlated with changes in HOMA-IR and HOMA-β; negatively correlated with changes in serum ketone and urinary glucose-to-creatinine ratio
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →